Long-term benefits of 5 years of tamoxifen: 10-Year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages 1657-1663

  Hackshaw, Allan ^a   Roughton, Michael ^a   Forsyth, Sharon ^a   Monson, Kathryn ^a   Reczko, Krystyna ^a   Sainsbury, Richard ^a   Baum, Michael ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EARLY CANCER; ENDOMETRIUM CANCER; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RISK REDUCTION; THERAPY EFFECT; TREATMENT DURATION; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; TAMOXIFEN;

EID: 79955602736     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2933     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of randomised trials. Lancet 365:1687-1717, 2005
3. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer: Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. J Natl Cancer Inst 88:1834-1839, 1996
4. Nordenskjöld B, Rosell J, Rutqvist LE, et al: Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial. J Natl Cancer Inst 97:1609-1610, 2005 (Pubitemid 41662715)
5. Keenan NG, Locca D, Varghese A, et al: Magnetic resonance of carotid artery ageing in healthy subjects. Atherosclerosis 205:168-173, 2009
6. Ewer MS, Gluck S: A woman's heart: The impact of adjuvant endocrine therapy on cardiovascular health. Cancer 115:1813-1826, 2009
7. Love RR, Wiebe DA, Feyzi JM, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86:1534-1539, 1994 (Pubitemid 24330218)
8. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, et al: Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 147:1093-1099, 2004 (Pubitemid 38880970)
9. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776-782, 1997 (Pubitemid 27242278)
10. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995
11. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005 (Pubitemid 41672231)
12. Belfiglio M, Valentini M, Pellegrini F, et al: Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 104:2334-2339, 2005 (Pubitemid 41691553)
13. Rutqvist LE, Johansson H: Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46:133-145, 2007 (Pubitemid 46277056)
14. Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology 71:1-9, 2006
15. Ziller V, Kalder M, Albert US, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436, 2009
16. Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004 (Pubitemid 41103687)
17. Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328, 2001 (Pubitemid 32112842)
18. Barron TI, Connolly R, Bennett K, et al: Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 109:832-839, 2007 (Pubitemid 46333524)
19. Kahn KL, Schneider EC, Malin JL, et al: Patient centered experiences in breast cancer: Predicting long-term adherence to tamoxifen use. Med Care 45:431-439, 2007
20. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003 (Pubitemid 46621892)
21. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008
22. Güth U, Huang DJ, Schötzau A, et al: Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99:428-433, 2008
23. Lash TL, Fox MP, Westrup JL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220, 2006 (Pubitemid 44268270)
24. Owusu C, Buist DS, Field TS, et al: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549-555, 2008 (Pubitemid 351264347)
25. Grunfeld EA, Hunter MS, Sikka P, et al: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97-102, 2005 (Pubitemid 41399883)
26. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
27. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
28. Yamamoto Y, Iwase H: Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol 13:384-394, 2008
29. Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007
30. Breastcancer.org: Aromatase inhibitors. http://www.breastcancer.org/ treatment/hormonal/aromatase-inhibitors/
31. Clinical Trial Service Unit and Epidemiological Studies Unit: Fact sheet: Questions and answers about the overview and tamoxifen. http://www.ctsu.ox.ac. uk/pressreleases/1998-05-16/fact-sheet
32. British National Formulary 59. http://bnf.org/bnf/